RxDoctor Payments Data

Amy Hollen, MD

Family Medicine · Grand Rapids, MINPI 1750463816

Payments from drug & device makers

$6,804in general payments, 2019–2025

Across 410 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$842
  • Lilly USA, LLC$372
  • GSK$348
  • Pfizer$287
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,70499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,804 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$19,681
Medicare patients
69
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide60$64,926
TrulicityDulaglutide26$53,310
EliquisApixaban47$51,567
OzempicSemaglutide30$45,201
FarxigaDapagliflozin Propanediol21$32,755
JardianceEmpagliflozin20$31,156
XareltoRivaroxaban19$26,152
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,756
MyrbetriqMirabegron11$10,522
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,204
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$8,698
Atorvastatin Calcium369$6,723
Combivent RespimatIpratropium/Albuterol Sulfate12$6,050
Levothyroxine Sodium323$6,016
Liothyronine Sodium104$5,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$372$118,23686 claims
PfizerEliquis$287$51,56747 claims
Novo NordiskOzempic$842$45,20130 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,077$42,95932 claims
Boehringer IngelheimJardiance, Combivent Respimat$52$37,20632 claims
Johnson & JohnsonXarelto$157$26,15219 claims
GSKTrelegy Ellipta$348$10,75613 claims
Astellas Pharma US IncMyrbetriq$252$10,52211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →